<PAGE> 

                     SECURITIES AND EXCHANGE COMMISSION              Conformed
                           Washington, D.C. 20549                       Copy    

                                FORM 10-Q/A

          (Mark One)
          [X]  QUARTERLY REPORT PURSUANT TO SECTION 13
               OR 15(d) OF THE SECURITIES EXCHANGE ACT OF        
               1934
               
          For the quarterly period ended September 30, 1998
                                         ------------------
                                OR

          [ ]  TRANSITION REPORT PURSUANT TO SECTION 13
               OR 15(d) OF THE SECURITIES EXCHANGE ACT OF        
               1934

          For the transition period from                to   
                                          -------------     ------------       

                Commission file number 333-02015 
                                       ---------

                             CYTOGEN Corporation
                                                                 

            (Exact name of Registrant as specified in its charter)

           Delaware                                       22-2322400          
-------------------------------                     -----------------------     
(State or Other Jurisdiction  of                       (I.R.S. Employer   
Incorporation or Organization)                      Identification Number)


           600 College Road East, CN 5308, Princeton, NJ 08540-5308
           --------------------------------------------------------  
            (Address of Principal Executive Offices and Zip Code)

     Registrant's telephone number, including area code (609) 987-8200

     Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days:  Yes X  No   .

     Indicate the number of shares outstanding of each of the
issuer's classes of common stock, as of the latest practicable
date:

           Class                       Outstanding at October 26, 1998   
-----------------------------          -------------------------------  
Common Stock, $.01 par value                      58,604,950                




<PAGE>

PART II  -  OTHER INFORMATION

 Item 6  -        Exhibits and Reports on Form 8-K

     (a) Exhibits: 

      1. Amended and Restated Rights Agreement, dated as of
         October 19, 1998 between CYTOGEN Corporation and Chase
         Mellon Shareholder Services, L.L.C., as Rights Agent. 
         The Amended and Restated Rights Agreement includes the
         Form of Certificate of Designations of Series C Junior
         Preferred Stock as Exhibit A, the form of Rights 
         Certificate as Exhibit B and the Summary of Rights as 
         Exhibit C.  Filed herewith.

      10.1    Employment agreement effective as of August 20,
              1998 between CYTOGEN Corporation and H. Joseph
              Reiser.  Filed herewith.

      10.2    Loan and Security Agreement, dated as of October
              19, 1998 between CYTOGEN Corporation and the CIT
              Group/Credit Finance, Inc.  Filed herewith.

      10.3    Private Equity Line Agreement by and between
              Kingsbridge Capital Limited and CYTOGEN Corporation
              dated as of October 23, 1998.  Filed herewith.

      10.4    License Agreement by and between Berlex Laboratories, Inc. 
              and CYTOGEN Corporation dated as of October 28, 1998.  
              Filed herewith. 

      10.5    Addendum to the Letter Agreement effective as of
              October 29, 1998 between CYTOGEN Corporation and
              DuPont Pharmaceuticals Company.  Filed herewith.

      27      Financial Data Schedule (Submitted to SEC only in
              electronic format).



<PAGE>

                               SIGNATURES



      Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.


                                            CYTOGEN CORPORATION





Date December 30, 1998                      By /s/ Jane M. Maida  
     -----------------                         ------------------
                                               Jane M. Maida
                                               Chief Accounting Officer
                                               (Authorized Accounting Officer)